Juno Therapeutics' cell therapy trial is put on hold

04/10/2014 | Forbes

Two patient deaths during a clinical trial of Juno Therapeutics' chimeric antigen receptor therapy have prompted a halt to the initiation of treatment for new patients until changes are made to the study. The deaths were related to cytokine release syndrome. Juno Therapeutics and Memorial Sloan-Kettering Cancer Center are taking steps to prevent future deaths, and the trial could continue in several weeks pending an FDA review.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Children's Health Plan
Houston, TX
Chief Information Officer
Meridian Health Plan
Detroit, MI
Actuary
NTA Life
Addison, TX
Vice President - Government Products
Health Alliance Plan
Detroit, MI